2014 Press Releases

2017 | 2016 | 2015 | 2014 | 2013 | 2012

AMAG Pharmaceuticals and Takeda Announce Mutual Termination of Agreement to License, Develop and Commercialize Ferumoxytol in Ex-U.S. Territories, Including Europe

WALTHAM, Mass. and OSAKA, Japan, Dec. 29, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals (Nasdaq:AMAG) and Takeda Pharmaceutical Company Limited (Takeda) announced today that they have entered into an agreement to mutually terminate the March 2010 license, development and commercialization agreement,... More > 

AMAG Pharmaceuticals Announces Presentation at Jefferies 2014 Global Healthcare Conference in London

WALTHAM, Mass., Nov. 14, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG), a specialty pharmaceutical company, announced today that William Heiden, AMAG's president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference in London on Thursday, No... More > 

AMAG Pharmaceuticals Completes Acquisition of Lumara Health's Maternal Health Business

-AMAG Closes $340 Million Term Loan -AMAG and Lumara Health Reaffirm Commitment to Women's Health and Reducing the Risks of Preterm Birth -Lumara Executive Ken Wilson to Lead Maternal Health Division within AMAG WALTHAM, Mass., Nov. 12, 2014 /PRNewswire/ -- AMAG Pharmaceuticals, Inc. (AMAG)... More > 

AMAG Pharmaceuticals Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2014

20% Growth Results in Record U.S. Feraheme Sales Lumara Health Acquisition on Track to Close in Fourth Quarter Conference call scheduled for 8:00 a.m. EDT today WALTHAM, Mass., Oct. 30, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG), a specialty pharmaceutical company... More > 

AMAG Pharmaceuticals, Inc. to Host Conference Call on October 30, 2014 at 8:00 a.m. ET to Discuss Financial Results for the Quarter and Nine Months Ended September 30, 2014

WALTHAM, Mass., Oct. 27, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will report unaudited consolidated financial results for the quarter and nine months ended September 30, 2014 before the U.S. financial markets open on Thursday, October 30, 2014. The announ... More > 

AMAG Pharmaceuticals to Acquire Lumara Health Maternal Health Business

Accelerates transformation of AMAG to a Profitable, Multi-Product Specialty Pharmaceutical Company Adds FDA-Approved Therapy Makena® and Complementary Commercial Platform to AMAG Portfolio Projected Pro Forma Combined 2015 Revenues of $350 million and Estimated Annual Cost Synergies of a... More > 

AMAG Pharmaceuticals Appoints Judith Johnson, M.D. as Vice President of Pharmacovigilance and Pharmacoepidemiology

WALTHAM, Mass., Sept. 16, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that Judith Johnson, M.D., has rejoined the company as vice president of pharmacovigilance and pharmacoepidemiology. Dr. Johnson will have responsibility for all pharmacovigilance functions at... More > 

AMAG Pharmaceuticals Announces Appointment of John A. Fallon, M.D. to Board of Directors

WALTHAM, Mass., Sept. 8, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that John Fallon, M.D., senior vice president and chief physician executive at Blue Cross & Blue Shield of Massachusetts (BCBSMA), has been elected to AMAG's board of directors, effective S... More > 

AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

WALTHAM, Mass., Aug. 29, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that company management will discuss AMAG's business and financial outlook, strategy and growth prospects at investor conferences taking place in September 2014. On Wednesday, September 3, ... More > 

AMAG Pharmaceuticals Appoints Robert Blood as Vice President of Legal Affairs and Chief Compliance Officer

WALTHAM, Mass., Aug. 12, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Robert Blood, Esq. as vice president of legal affairs and chief compliance officer. Mr. Blood comes to AMAG with extensive experience in the pharmaceutical and healthcare ind... More > 

AMAG Pharmaceuticals, Inc. to Participate in Jefferies Boston Healthcare Summit

WALTHAM, Mass., Aug. 1, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that Frank Thomas, chief operating officer, and Scott Holmes, senior vice president of finance and investor relations, will host one-on-one meetings at the Jefferies 2014 Boston Healthcare Summi... More > 

AMAG Pharmaceuticals Announces Second Quarter and Six Month 2014 Financial Results and Updates Financial Guidance for 2014

Record Physician Demand Drives 27% Increase in U.S. Net Feraheme Revenues Strong Sales Growth and Disciplined Expense Management Generate Positive Operating Income Conference call scheduled for 8:00 a.m. EDT today WALTHAM, Mass., July 29, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, In... More > 

AMAG Pharmaceuticals, Inc. to Host Conference Call on July 29, 2014 at 8:00 a.m. ET to Discuss Financial Results for the Quarter and Six Months Ended June 30, 2014

LEXINGTON, Mass., July 25, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will report unaudited consolidated financial results for the quarter and six months ended June 30, 2014 before the U.S. financial markets open on Tuesday, July 29, 2014. The announcement w... More > 

AMAG Pharmaceuticals Appoints Melissa Bradford Klug as Senior Vice President of Business Development and Strategy

WALTHAM, Mass., June 11, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Melissa Bradford Klug as senior vice president of business development and strategy. Ms. Klug brings a wealth of hands-on business development, licensing and strategic partne... More > 

AMAG Pharmaceuticals Announces Patent Term Extension for Ferumoxytol in the U.S.

WALTHAM, Mass., June 6, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that the United States Patent and Trademark Office (USPTO) has issued a U.S. patent term extension certificate extending the term of U.S. Patent No. 6,599,498 by 1,209 days. With this extension ... More > 

AMAG Pharmaceuticals, Inc. to Present at the UBS Global Healthcare Conference

WALTHAM, Mass., May 13, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the UBS Global Healthcare Conference on Monday, May 19, 2014 at 3:00 p.m. ET in New York. The session will include a company ... More > 

Study Showing Effectiveness of MuGard(R) for Management of Oral Mucositis Featured in the Journal Cancer

WALTHAM, Mass., April 28, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that the publication of data from a multi-institutional trial of MuGard has been featured in the print edition of the journal Cancer, available today. MuGard is a mucoadhesive hydrogel that fo... More > 

AMAG Announces First Quarter 2014 Financial Results

17% Total Revenue Growth, Driven by Strong Feraheme Performance Favorable Terms Achieved in Recent $200 Million Convertible Debt Offering Ending Cash Balance of $385 Million Provides Capital for Portfolio Expansion Conference call scheduled for 8:00 a.m. Eastern time today WA... More > 

AMAG Pharmaceuticals, Inc. to Host Conference Call on April 24, 2014 at 8:00 a.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2014

WALTHAM, Mass., April 22, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will report unaudited consolidated financial results for the quarter ended March 31, 2014 before the U.S. financial markets open on Thursday, April 24, 2014. The announcement will be follow... More > 

AMAG Pharmaceuticals Announces Appointment of Jim Sulat to Its Board of Directors and the Transition of Chairman Role to Gino Santini

WALTHAM, Mass., April 16, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced new appointments to its board of directors. Current board member, Gino Santini, has been elected, by unanimous vote, to chairman of the board of directors, effective immediately, taking over f... More > 

AMAG Pharmaceuticals, Inc. to Present at the Needham Healthcare Conference

AMAG Pharmaceuticals, Inc. to Present at the Needham Healthcare Conference WALTHAM, MA (April 1, 2014) - AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William Heiden, AMAG’s chief executive officer, will present at the 13th Annual Needham Healthcare Conference on Wedn... More > 

AMAG Pharmaceuticals, Inc. to Participate in the Cowen and Company 34th Annual Healthcare Conference

WALTHAM, Mass., Feb. 27, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the Cowen and Company 34th Annual Healthcare Conference on Monday, March 3, 2014 at 4:10 p.m. ET in Boston. The session will... More > 

AMAG Pharmaceuticals Appoints Edward Jordan as Senior Vice President of Sales and Marketing

WALTHAM, Mass., Feb. 25, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Edward Jordan as senior vice president of sales and marketing. Mr. Jordan brings to AMAG more than 20 years of experience in U.S. and international pharmaceutical sales and m... More > 

Study Shows MuGard(R) is More Effective Than Sham-Control at Reducing Mouth and Throat Soreness Associated With Oral Mucositis in Head and Neck Cancer Patients

WALTHAM, Mass., Feb. 18, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the publication of data from a multi-institutional trial of MuGard in the online edition of the journal Cancer available at http://onlinelibrary.wiley.com/doi/10.1002/cncr.28553/full. MuGard is... More > 

AMAG Pharmaceuticals Announces Pricing of $175 Million of 2.50% Convertible Senior Notes Due 2019

WALTHAM, Mass., Feb. 12, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the pricing of $175 million aggregate principal amount of 2.50% Convertible Senior Notes due 2019 (the "notes") in an underwritten public offering (the "offering") registered under the Securiti... More > 

AMAG Pharmaceuticals Announces Proposed Offering of $150 Million of Convertible Senior Notes due 2019

WALTHAM, Mass., Feb. 10, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of Convertible Senior Notes due 2019 (the "notes") in an underwritten public offering (... More > 

AMAG Pharmaceuticals, Inc. to Participate in the Leerink Global Healthcare Conference

WALTHAM, Mass., Feb. 10, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will participate in an analyst-led fireside chat at the Leerink Global Healthcare Conference in New York, NY. The fireside chat will take pl... More > 

AMAG Provides Business Outlook for 2014 and Reports 2013 Financial Results

Achieves record annual U.S. Feraheme product revenues in 2013 with 28% growth over 2012 Guides to continued growth for Feraheme and first breakeven year in 2014 Conference call scheduled for 8:00 a.m. Eastern time today WALTHAM, Mass., Feb. 6, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmac... More > 

AMAG Pharmaceuticals, Inc. to Host Conference Call on February 6, 2014 at 8:00 a.m. ET to Discuss Financial Results for the Quarter and Year Ended 2013

WALTHAM, Mass., Feb. 4, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will report unaudited consolidated financial results for the fourth quarter and year ended December 31, 2013 before the U.S. financial markets open on Thursday, February 6, 2014. The announce... More > 

AMAG Pharmaceuticals Announces Issuance of New U.S. Patent for Ferumoxytol

WALTHAM, Mass., Jan. 31, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that the United States Patent and Trademark Office (USPTO) has issued a new U.S. patent to AMAG for ferumoxytol, U.S. Patent No. 8,591,864, Polyol and Polyether Iron Oxide Complexes as Pharmaco... More > 

AMAG Pharmaceuticals Receives Complete Response Letter From U.S. Food and Drug Administration for the Supplemental New Drug Application for Feraheme(R) for the Broader IDA Indication

Conference Call Scheduled for 7:30 a.m. ET Today WALTHAM, Mass., Jan. 22, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the supplemental new drug application (sNDA) for Fer... More > 

AMAG Pharmaceuticals, Inc. to Host Conference Call on January 22, 2014 at 7:30 a.m. E.T. to Provide a Regulatory Update

WALTHAM, Mass., Jan. 21, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will host a conference call to provide a regulatory update regarding the FDA's action on the company's supplemental new drug application for Feraheme® before the U.S. financial markets open ... More > 

AMAG Pharmaceuticals Announces Preliminary Fourth Quarter and Annual 2013 Financial Results

Achieves record annual U.S. Feraheme product revenues: approximately 28% growth over 2012 Generates positive cash flows for second consecutive quarter Exceeds cash guidance, ending year with $217 million in cash and investments WALTHAM, Mass., Jan. 13, 2014 (GLOBE NEWSWIRE) -- AMA... More > 

AMAG Pharmaceuticals, Inc. to Present at the 32nd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 9, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG), a specialty pharmaceutical company, announced today that William Heiden, AMAG's chief executive officer, will provide an update on the company followed by a breakout session at the 32nd Annual J.P. Morgan Heal... More > 

AMAG Pharmaceuticals Appoints Elizabeth Bolgiano as Senior Vice President of Human Resources

WALTHAM, Mass., Jan. 7, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Elizabeth Bolgiano as senior vice president of human resources. Ms. Bolgiano brings more than 20 years of experience across the spectrum of human resources disciplines, includ... More >